Inflammatory skin diseases account for an enormous physical and psychological burden. Although there have been tremendous improvements in the range of available treatments, there remains a major unmet medical need, not least of all because the majority of the advances are only approved for those with the most severe forms of disease. The other 80-90% of affected individuals are largely unable to benefit. Here, we aim to study the immune responses which are involved in driving skin ...

GO TO STUDY

This is a Phase 3, multi-center, randomized, double-blind, placebo controlled 3-arm study designed to assess the efficacy and safety of BHV7000 in participants with refractory focal epilepsy who are stable on at least one ASM. Participants must be considered uncontrolled on their current ASM regimen, defined as the occurrence of a minimum of an average of 6 seizures during an 8-week OP and no more than 21 consecutive days without a focal seizure in the OP. The study is planned to ...

GO TO STUDY

DESIGN An open label,pilot trial with a 12 month treatment period with randomisation to either IPE or standard of care. PRIMARY OBJECTIVE To evaluate the impact of icosapent ethyl (IPE) treatment on coronary inflammation - assessed by Fat Attenuation Index (FAI) Score. The hypothesis is that targeted treatment of participants with high vascular inflammation with IPE guided by the FAI-Score or CaRi-Heart® reduces vascular inflammation to a greater extent compared to the standard of care treatment in the NICE Guidelines.

GO TO STUDY

Head and neck cancer affects the mouth, throat, salivary glands, voice box, nose or sinuses. Every year over 12,000 people get head and neck cancer. It is the 8th most common form of cancer. Over recent years many more people, particularly young people, have developed head and neck cancers. Many of these cancers are removed surgically. Some people also need radiotherapy or chemotherapy. Treatments are improving and better at getting rid of these cancers. Neck dissection is a common operation ...

GO TO STUDY

Patients with the rare inherited bleeding disorders, afibrinogenaemia and dysfibrinogenaemia commonly require concentrated fibrinogen therapy to treat or prevent bleeding. Recent studies have highlighted that each type of fibrinogen treatment works a little differently, in particular in the degree to which a strong blood clot, that doesn't dissolve rapidly, is formed. We have recently studied the different effects of two commercial fibrinogen concentrates (Riastap®and Fibryga®) on clot formation in a patient with afibrinogenaemia. Our report suggests that the specific choice ...

GO TO STUDY

This is a study putting together large numbers of patients with or without a hereditary risk of adrenal tumours including tumours such as adrenocortical carcinoma and phaeochromocytoma/paraganglioma. The purpose is to answer questions about the survival of patients with these rare tumours and to do this, we will collect information on diagnosis and management of these tumours. This data will be best assessed by combing these rare cases at a national level recruiting from centres throughout UK and Ireland. The ...

GO TO STUDY

Millions of people suffer due to cardiac arrest every year and in many cases, the cause of the cardiac arrest is related to a disorder of the electrical activity of the heart. Calcium Release Deficiency Syndrome (CRDS) is a recently discovered electrical heart disorder that develops due to a genetic change in the RyR2 gene resulting in the low activity of RyR2 protein. Currently, CRDS needs genetic testing to be diagnosed and then the identified RyR2 genetic change needs to ...

GO TO STUDY

There are many types of dementia. This research studies the family of illnesses known as Frontotemporal type of dementia. This devastating group of illnesses change behaviour, language, and movement. Frontotemporal dementia often affects younger adults and runs in families. There is long running inflammation in the brain with Frontotemporal dementia – suggesting that anti-inflammatory treatments might slow or prevent decline. However, no two people are the same in their symptoms, or in what drives inflammation. For example, genetics, lifestyle, ethnicity ...

GO TO STUDY

We are conducting a study to gather more information on the safety and effectiveness of Xromi (hydroxyurea), a liquid medicine licensed to treat sickle cell disease (SCD) in children from 9 months of age. We aim to understand its safety profile and efficacy in preventing serious SCD complications (e.g., pain crises, acute chest syndromes, stroke) in children under 2 years when used in standard care. We will compare medical information collected during routine clinical appointments of children under 2 years who ...

GO TO STUDY

Patients with chronic obstructive pulmonary disease-obstructive sleep apnoea (COPD-OSA) overlap syndrome have higher rates of COPD exacerbations compared to patients with similar severity COPD without OSA. It is currently not known whether treating OSA in those with COPD-OSA overlap reduces exacerbation rates. COPD exacerbations are characterised by acute transient worsening of symptoms such as dyspnoea, sputum production, sputum purulence and cough which are above the normal day to day variation in symptom burden and are usually associated with escalation of ...

GO TO STUDY